Morbid obesity in a child with monosomy 1p36 syndrome

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Zagalo, Ana ^a   Dias, Patricia ^b   Pereira, Carla ^b   De Lurdes Sampaio, Maria ^b  

^a Hospital de Santo Andre   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CAPTOPRIL; METFORMIN; TOPIRAMATE;

ADENOTONSILLECTOMY; AGGRESSION; AIRWAY PRESSURE; APGAR SCORE; ARTICLE; ASSISTED VENTILATION; BODY MASS; CASE REPORT; CHILD; DISEASE ASSOCIATION; FAMILY HISTORY; FOLLOW UP; GENE; GENE DELETION; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; MONOSOMY 1P36 SYNDROME; MORBID OBESITY; PREMATURE LABOR; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SGCC GENE; SLEEP APNEA SYNDROME; WEIGHT CONTROL;

EID: 84860798896     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.01.2012.5503     Document Type: Article

References (8)

1. Battaglia A, Shaffer LG. 1p36 Deletion Syndrome. GeneReviews 2008.
2. Slavotinek A . Chromosome 1p36 deletions. Orphanet encyclopedia 2003:1-4.
3. Battaglia A, Hoyme HE, Dallapiccola B, et al. Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics 2008;121:404-10. (Pubitemid 351198468)
4. D'Angelo CS, Kohl I, Varela MC, et al. Extending the phenotype of monosomy 1p36 syndrome and mapping of a critical region for obesity and hyperphagia. Am J Med Genet A 2010;152A:102-10.
5. Stochholm K, Juul S, Gravholt CH. Diagnosis and mortality in 47,XYY persons: a registry study. Orphanet J Rare Dis 2010;5:15.
6. Rosenfeld JA, Crolla JA, Tomkins S, e t al. Refinement of causative genes in monosomy 1p36 through clinical and molecular cytogenetic characterization of small interstitial deletions. Am J Med Genet A 2010;152A:1951-9.
7. American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007;119:618.
8. McCrindle BW, Urbina EM, Dennison BA, et al.; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientifi c statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-67.